State Street SPDR S&P Biotech ETF
122 hedge funds and large institutions have $1.22B invested in State Street SPDR S&P Biotech ETF in 2013 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 44 increasing their positions, 39 reducing their positions, and 19 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more ownership
Funds ownership: →
more capital invested
Capital invested by funds: $ → $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
2% less funds holding
Funds holding: 125 → 122 (-3)
11% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 19
40% less funds holding in top 10
Funds holding in top 10: 5 → 3 (-2)
Holders
122
Holding in Top 10
3
Calls
$41.9M
Puts
$7.04M
Top Buyers
| 1 | +$101M | |
| 2 | +$74.5M | |
| 3 | +$31.8M | |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$18.8M |
| 5 |
Barclays
London,
United Kingdom
|
+$16.8M |
Top Sellers
| 1 | -$26.1M | |
| 2 | -$17.3M | |
| 3 | -$12.2M | |
| 4 |
NCM
Niemann Capital Management
Stateline,
Nevada
|
-$11.4M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$9.06M |